TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEngine, Inc. (TWO:4162) announced today that together with PharmaEngine’s partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), we reach the goal of patient enrollment in the global phase 3 metastatic pancreatic cancer study of PEP02 (MM-398). The total target number of patient enrollment is 405. The first patient received the first dose of MM-398 in January 2012.
Help employers find you! Check out all the jobs and post your resume.
